We conducted a subtype-specific GWAS, unlike other previous studies that had conducted a GWAS for overall breast cancer before stratifying by ER, PR, and HER2 status because breast cancer is considered as a heterogeneous disease for which the prognosis varies across subtypes[34]. This evidence concerns the gene PGR and breast cancer.